Highbridge Capital Management’s Ionis Pharmaceuticals IONS Stock Holding History

Highbridge Capital Management’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-11,100	Closed	-$259K	–	1481
2016 Q2	$259K	Buy	+11,100	New	+$358K	﹤0.01%	1126
2015 Q3	–	Sell	-21,700	Closed	-$1.25M	–	1684
2015 Q2	$1.25M	Sell	21,700 -1,200	-5%	-$76.3K	0.02%	661
2015 Q1	$1.46M	Buy	+22,900	New	+$1.55M	0.02%	631
2014 Q4	–	Sell	-8,200	Closed	-$318K	–	1282
2014 Q3	$318K	Sell	8,200 -1,800	-18%	-$63.8K	﹤0.01%	986
2014 Q2	$345K	Buy	+10,000	New	+$315K	﹤0.01%	831
2013 Q3	–	Sell	-88,300	Closed	-$2.37M	–	1400
2013 Q2	$2.37M	Buy	+88,300	New	+$1.88M	0.02%	455

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Highbridge Capital Management's IONS Position: Q1 2020 in Review

Highbridge Capital Management sold out of Ionis Pharmaceuticals (IONS) in Q1 2020, closing a stake of 96,060 shares — an estimated $5.8M sold.

Highbridge Capital Management first reported a position in IONS in Q2 2015 and held it in 3 quarters. The position peaked at $5.8M in Q4 2019. 363 funds tracked by Wall St. Rank hold IONS as of Q1 2020.

Highbridge Capital Management reported no remaining Ionis Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Highbridge Capital Management sold 96,060 Ionis Pharmaceuticals shares in Q1 2020, an estimated $5.8M.
Highbridge Capital Management first reported a position in Ionis Pharmaceuticals in Q2 2015 and held it in 3 quarters.
Highbridge Capital Management's Ionis Pharmaceuticals position peaked at $5.8M in Q4 2019.
363 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2020.

Based on Highbridge Capital Management's 13F filing for Q1 2020, filed 15 May 2020.